-
Mashup Score: 26NTRK gene fusion testing and management in lung cancer - 2 day(s) ago
In non-small cell lung cancer (NSCLC), oncogene dysregulation due to activating mutations, fusions or amplifications is a frequent event. These recurring oncogenic alterations enable cancer cell survival and growth [1,2]. Lung cancers harbouring oncogenic drivers tend to rely on aberrant signalling for survival and growth, a concept known as ‘oncogene addiction’ [2,3]. This dependency on oncogene signalling, however, generates a unique vulnerability that can be exploited with the use of selective targeted agents such as tyrosine kinase inhibitors (TKIs) [2,4].
Source: www.cancertreatmentreviews.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 0【#健康探索號】癌症點為之罕見?康復率比常見癌症低?比其他癌症更難察覺? - 3 day(s) ago
癌症可怕,罕見癌症更可怕?!今集主持陳心怡請嚟內科腫瘤科專科醫生龍浩鋒,拆解罕見癌症謬誤,以及癌症先兆!💪🏻想知更多健康資訊,即刻瀏覽以下網頁 https://bit.ly/3PWHgPK 好多疾病嘅成因同治療方法,其實都係以訛傳訛!🗣《健康探索號》主持陳心怡每集請嚟唔同專科醫生👨🏻,講解各種疾病成因…
Source: www.youtube.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 2
The WHO Symposium is convening individuals with lived experience, through formally recognizing their knowledge and expertise in co-creating and co-implementing NCD policies, programmes, and services that are responsible, equitable, holistic, and contextually appropriate. The event series will offer a platform for knowledge exchange and collaboration, facilitating strategic alliances between individuals with lived experience and its Member States, and developing strategic inputs towards the upcoming 4HLM
Source: knowledge-action-portal.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 11
Dowdy Jackson, Ph.D.Jackson Consulting GroupMay 10th 2024 AbstractAntibody drug conjugates (ADCs) have become one of the most sought after modalities to treat cancer patients. Several high-profile deals have been announced recently between smaller biotech companies developing ADCs and larger companies looking to enhance their oncology pipelines. There is significant competition in the ADC space and one of the key questions for companies developing ADCs is how can they differentiate from their co
Source: www.jackson-consulting-group.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 11
Dowdy Jackson, Ph.D.Jackson Consulting GroupMay 10th 2024 AbstractAntibody drug conjugates (ADCs) have become one of the most sought after modalities to treat cancer patients. Several high-profile deals have been announced recently between smaller biotech companies developing ADCs and larger companies looking to enhance their oncology pipelines. There is significant competition in the ADC space and one of the key questions for companies developing ADCs is how can they differentiate from their co
Source: www.jackson-consulting-group.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 11
Dowdy Jackson, Ph.D.Jackson Consulting GroupMay 10th 2024 AbstractAntibody drug conjugates (ADCs) have become one of the most sought after modalities to treat cancer patients. Several high-profile deals have been announced recently between smaller biotech companies developing ADCs and larger companies looking to enhance their oncology pipelines. There is significant competition in the ADC space and one of the key questions for companies developing ADCs is how can they differentiate from their co
Source: www.jackson-consulting-group.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 3Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book - OncoDaily - 1 month(s) ago
Erman Akkus: NSCLC and anti-EGFR treatments from the ASCO Educational Book / ADAURA, ADAURA2, ADJUVANT/CTONG 1104, Ankara University, anti-EGFR treatments,
Source: oncodaily.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1instagram - 2 month(s) ago
A virtual Experts Knowledge Share on the topic of ‘Precision oncology in practice – The journey from testing to treatment in lung and prostate cancer’ chaired by Prof. Fernando López-Ríos (Spain) and co-chaired by Assoc. Prof. Alicia Morgans (US) and Assoc. Prof. Herbert Loong (Hong Kong) This event is in collaboration with PRECISION ONCOLOGY CONNECT, a group of international experts in the field of detection and treatment of targetable genetic/genomic alterations in various cancers. You will also have
Source: engage.cor2ed.comCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 1
Learn the latest about epithelioid hemangioendothelioma (EHE) research and clinical management from an international group of experts and attendees on Friday, April 19, 2024.
Source: fightehe.orgCategories: General Medicine News, Oncologists2Tweet
-
Mashup Score: 2Current and Future Treatments of Vascular Cognitive Impairment - 2 month(s) ago
Correspondence to: Vincent Chung Tong Mok, MD, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32, Ngan Shing St, New Territories, Hong Kong SAR, China. Email For Sources of Funding and Disclosures, see page 832. Correspondence to: Vincent Chung Tong Mok, MD, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, 30-32, Ngan Shing St, New Territories, Hong
Source: www.ahajournals.orgCategories: General Medicine News, Oncologists2Tweet
We have recently published our latest recommendations for #NTRK #fusion #testing & #management in #lungcancer. Full paper here: https://t.co/xasfc8M7Qq #MatteoRepetto @GarassinoMarina @tonymok9 @peters_solange @dplanchard @DrSanjayPopat @alexdrilon #FernadoLopezRios… https://t.co/0QXzjSnFJ8